Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...

Edwards Lifesciences (NYSE:EW) today announced its plans for significant growth as a purely structural heart company in 2025.

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...

which is anticipated to offer fresh insights for global implanters treating symptomatic severe aortic stenosis (SASS). The ...

A recent study has revealed a strong link between insulin resistance and an increased risk of aortic stenosis (AS), a ...

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Insulin resistance can increase the risk of aortic stenosis -- a common heart valve disease, in men over the age of 45, finds ...

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

Insulin resistance associated with prediabetes appears to raise a person’s risk of a common and serious heart valve ...

Edwards Lifesciences (EW) reaffirmed original 2024 total company constant currency sales growth guidance of 8% to 10%. The company is ...

Dale Hamer, a veteran NFL official who later served as a replay official, has passed away at the age of 87. Hamer died on ...

FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural ...